Targets › PPOX
12 programs from 11 companies in 13 trials: 6 Phase 1, 4 Phase 2, 2 Phase 3, 1 Phase 4; Oncology, Immunology; next expected readout Nov 2026.
Catalyzes the 6-electron oxidation of protoporphyrinogen-IX to form protoporphyrin-IX. (UniProt, P50336)
Open in Phaseline: the race on PPOX, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Psoriasis Treatment Center of Central New Jersey | Ameluz 10% Topical Gel Aminolevulinic acid (ALA) for photodynamic therapy; ALA is converted to protoporphyrin IX | PPOX | Phase 4 | Actinic Keratoses | Nov 2026 |
| Sun Pharmaceutical Industries | Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA Aminolevulinic acid prodrug for photodynamic therapy; converted to protoporphyrin IX for p | PPOX | Phase 3 | Actinic Keratosis | Jan 2027 |
| Lee's Pharmaceutical | 5-Aminolevulinic Acid Hydrochloride Powder for Oral Solution 5-ALA is a prodrug that accumulates protoporphyrin IX in tumor cells; fluorescence is used | PPOX | Phase 3 | 5-aminolevulinic Acid | Dec 2027 |
| Case Comprehensive Cancer Center | ALA (Levulan) Prodrug for photodynamic therapy; metabolized to protoporphyrin IX to generate reactive ox | PPOX | Phase 2 | Basal Cell Carcinoma | Sep 2027 |
| Henry Ford Health System | 5-Aminolevulinic acid Hydrochloride (Gliolan®) Fluorescent imaging agent that induces protoporphyrin IX accumulation for photodynamic dia | PPOX | Phase 2 | Upper Tract Urothelial Carcinoma; Kidney Cancers | Dec 2027 |
| University Hospital, Lille | 5-Aminolevulinic Acid (5-ALA) Photosensitizer that accumulates in tumors and generates singlet oxygen upon light activat | PPOX | Phase 2 | Mesotheliomas Pleural | – |
| Nathalie Zeitouni | aminolevulinic acid HCL (ALA) Prodrug converted to protoporphyrin IX for photodynamic therapy | PPOX | Phase 1 | Basal Cell Carcinoma (BCC) | Dec 2026 |
| Shayan Moosa, MD | 5-ALA Photosensitizer prodrug (converts to protoporphyrin IX); used in sonodynamic therapy to ge | PPOX | Phase 1 | Recurrent Glioblastoma | Dec 2026 |
| Sun Pharmaceutical Industries | Levulan Kerastick (reformulated) 5-aminolevulinic acid (ALA) prodrug for photodynamic therapy | PPOX | Phase 1 | Actinic Keratosis (AK) | Dec 2026 |
| Universität Münster | Gliolan (5-Aminolevulinic acid) Protoporphyrin IX precursor; photosensitizer for radiodynamic therapy | PPOX | Phase 1 | Glioblastoma | Jan 2028 |
| Roswell Park Cancer Institute | Aminolevulinic Acid Photosensitizing agent converted to protoporphyrin IX in cancer cells; emits red fluoresce | PPOX | Phase 1 | Locally Advanced Colorectal Carcinoma | Jun 2029 |
| Hemerion Therapeutics | 5-ALA HCl intraoperative Photodynamic Therapy (PDT) Photodynamic therapy using 5-aminolevulinic acid as a photosensitizer | PPOX | Phase 1 | Primary Glioblastoma | – |
Actinic Keratosis (AK) (1) Basal Cell Carcinoma (BCC) (1) Primary Glioblastoma (1) Actinic Keratosis (1) Basal Cell Carcinoma (1) Actinic Keratoses (1) Glioblastoma (1) 5-aminolevulinic Acid (1) Upper Tract Urothelial Carcinoma (1) Kidney Cancers (1) Recurrent Glioblastoma (1) Mesotheliomas Pleural (1)
small molecule (9), antibody (1)
Sun Pharmaceutical Industries (2) Nathalie Zeitouni (1) Hemerion Therapeutics (1) Case Comprehensive Cancer Center (1) Psoriasis Treatment Center of Central New Jersey (1) Universität Münster (1) Lee's Pharmaceutical (1) Henry Ford Health System (1) Shayan Moosa, MD (1) University Hospital, Lille (1) Roswell Park Cancer Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.